Apr 16, 2026 Log in

Partnership

FRONTEO and Astellas Pharma Sign Agreement on Target Molecule Discovery

Citation-Grade Primary-source linked Schema.org verified NQ 0 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Apr 16, 2026 4:00 PM ・ Updated Jun 18, 2026 12:12 AM ・ 2 min read ・ Source: PR TIMES

Show contents

⚡ Key Points

AI company FRONTEO and Astellas Pharma have signed an agreement regarding target molecule discovery in drug creation.
FRONTEO will provide its proprietary specialized AI, 'KIBIT,' to support Astellas Pharma's drug discovery research.

AI company FRONTEO and Astellas Pharma have signed an agreement regarding target molecule discovery in drug creation. FRONTEO will provide its proprietary specialized AI, 'KIBIT,' to support Astellas Pharma's drug discovery research.

PRIMARY SOURCE PR TIMES View source Distributor: PR TIMES
Published: Apr 16, 2026

Our group provides solutions based on our proprietary specialized AI 'KIBIT' in four businesses requiring expertise in life sciences, economic security, business intelligence, and legal tech. KIBIT is a domestically produced AI that supports expert decision-making using natural language processing technology (patented in Japan, the US, and Europe) and structuring technology that maps analysis results (patented in Japan and the US).

FACT BOX

Source: PR TIMES
Category: Partnership
Organizations: FRONTEO
Products / services: KIBIT

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Apr 16, 2026 4:00 PM — Distributor PR TIMES
Collected　Apr 16, 2026 4:31 PM
AI structured & analyzed　Apr 19, 2026 1:24 AM
Desk-reviewed & published　Apr 16, 2026 4:00 PM

FAQ

What is the agreement signed between FRONTEO and Astellas Pharma about?

The agreement signed between FRONTEO and Astellas Pharma is on target molecule discovery.

What is the name of the proprietary specialized AI used to provide solutions?

The proprietary specialized AI used to provide solutions is named 'KIBIT'.

In which four areas does the group provide KIBIT-based solutions requiring expertise?

KIBIT-based solutions are provided in life sciences, economic security, business intelligence, and legal tech.

Where is the natural language processing technology of KIBIT patented?

The natural language processing technology used by KIBIT is patented in Japan, the United States, and Europe.

What kind of technology maps analysis results and where is it patented?

Structuring technology maps analysis results and is patented in both Japan and the United States.

Cite this article — HOW TO CITE

Washin AI News Desk“FRONTEO and Astellas Pharma Sign Agreement on Target Molecule Discovery”AI News by Washin Village（和心村）, Apr 16, 2026. https://aeo.washinmura.jp/ai/fronteo-com/en/news/2026-04-19-fronteo-and-astellas-pharma-sign-agreeme

AI CRAWLER ACTIVITY

as of Jul 1, 2026

AI crawler visits to this article (cumulative)31 bots

Site-wide cumulative

ClaudeBot

bot_visits_summary

4663k

last Jul 1, 2026

GPTBot

bot_visits_summary

3076k

last Jul 1, 2026

Bingbot

bot_visits_summary

1859k

last Jul 1, 2026

Google AI

bot_visits_summary

1790k

last Jul 1, 2026

Googlebot

bot_visits_summary

1306k

last Jul 1, 2026

Meta AI

bot_visits_summary

691k

last Jul 1, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← fronteo-com Back to newsroom (88)

Copied